What Are Timolol Eye Drops Used For?

Timolol eye drops are one of the oldest and most widely prescribed topical treatments for glaucoma and ocular hypertension, having entered clinical use in the late 1970s. They work by reducing the amount of fluid the eye produces, which lowers internal eye pressure. In clinical studies, timolol typically lowers intraocular pressure by roughly 20 to 30 percent, and it remains a first-line option even as newer drug classes have emerged. But timolol’s story is more layered than a straightforward glaucoma medication: it gets absorbed into the bloodstream far more than most people realize, it interacts with common antidepressants in ways that can be dangerous, and it has found surprising second lives in treating infant birthmarks, chronic wounds, and even migraines.

How Timolol Lowers Eye Pressure

Your eye constantly produces a clear fluid called aqueous humor, which nourishes the lens and cornea and then drains out through a mesh-like channel. When production outpaces drainage, pressure builds inside the eye, and over time that elevated pressure can damage the optic nerve. Timolol is a beta-blocker, and its primary job in the eye is to slow down fluid production by the ciliary epithelium, the tissue responsible for secreting aqueous humor. The conventional explanation is that timolol blocks beta-adrenergic receptors on those cells, which reduces a chemical signaling cascade that drives secretion. Research has also identified at least one additional mechanism: timolol appears to interfere with chloride and bicarbonate exchange across the ciliary epithelium through a pathway that operates independently of the classical receptor-blocking route.¹ This dual action may explain why timolol is such a reliable pressure-lowering drug.

In a large multicenter study of patients with open-angle and capsular glaucoma, timolol used alone produced a mean pressure drop of about 9.4 mmHg, a reduction of roughly 29 percent from baseline.² That degree of lowering is often enough to bring a patient from a risky pressure level into a safer range, though whether it is sufficient depends on the individual’s target pressure and disease severity.

How Timolol Compares to Newer Medications

Since the 1990s, prostaglandin analogs like latanoprost have become the dominant first-line therapy for open-angle glaucoma. In head-to-head trials, latanoprost consistently outperforms timolol. A 12-week study found that latanoprost reduced pressure by about 6.2 mmHg compared with 4.4 mmHg for timolol.³ A six-month trial found a similar gap, with latanoprost lowering pressure by about 6.7 mmHg versus 4.9 mmHg for timolol, and four timolol patients had to be withdrawn because their pressure was not controlled well enough.⁴

Prostaglandin analogs also work by a completely different mechanism: instead of reducing fluid production, they increase the outflow of fluid from the eye. This difference is what makes timolol and prostaglandin analogs so effective when combined. And prostaglandins have fewer systemic side effects because they do not act on the heart or lungs. Still, timolol has not vanished from practice. It is inexpensive, available generically worldwide, and remains the backbone of many combination products. Some patients tolerate it perfectly well. And for certain individuals who cannot use prostaglandin analogs, whether because of iris color changes, eyelash growth, or periorbital fat loss, timolol stays in the rotation.

Combination Therapy

Many glaucoma patients need more than one drug to keep pressure at target. Timolol pairs well with other classes because it works through a distinct mechanism. The most widely used fixed-dose combination is latanoprost plus timolol, first launched in the European Union in 2001. This combination consistently achieves greater pressure reduction than either drug alone and, in several studies, outperformed other combination products as well.⁵ A fixed-combination bottle simplifies life for the patient: one drop instead of two, applied once a day, which tends to improve adherence.

Timolol is also combined with carbonic anhydrase inhibitors like dorzolamide and brinzolamide. A meta-analysis of the dorzolamide-timolol combination found that it lowered pressure by about 3.8 mmHg at trough and roughly 4.9 mmHg at peak.⁶ In a direct comparison, adding either brinzolamide or dorzolamide to timolol produced similar additional reductions of about 14 to 22 percent on top of what timolol was already doing.⁷ In practice, the choice between these add-ons often comes down to comfort: dorzolamide stings more on instillation, while brinzolamide is a suspension that can blur vision briefly.

Systemic Absorption and Why It Matters

People tend to assume eye drops stay in the eye. They do not. After you put a drop on the surface of the eye, a substantial fraction drains through the nasolacrimal duct, the tiny canal that connects the inner corner of your eye to the inside of your nose. From there it hits the nasal mucosa, which is richly supplied with blood vessels and lacks the first-pass liver metabolism that would break down an oral pill before it reaches the general circulation. A review of human studies confirmed that topically applied timolol, along with several other ophthalmic drugs, absorbs rapidly into the systemic circulation.⁸

The clinical consequence is that timolol eye drops can act like a small oral dose of a beta-blocker. For most healthy adults, the amount that reaches the bloodstream is small enough that they never notice. But for people with asthma, chronic obstructive pulmonary disease, slow heart rates, or certain types of heart block, even a small systemic dose of a non-selective beta-blocker can cause real trouble.

Cardiopulmonary Risks

The most feared side effects of timolol eye drops involve the heart and lungs. Because timolol is non-selective, blocking both beta-1 and beta-2 receptors, it can slow the heart rate, lower blood pressure, and constrict the airways. Published case reports describe severe, life-threatening bronchospasm, including cases that progressed to hypoxic cardiac arrest, in patients with COPD and asthma.⁹ In one provocation test, two drops of the 0.25 percent concentration, the lower-strength formulation, reduced a patient’s lung function by 56 percent and caused significant slowing of the heart.¹⁰

Cardiac effects include symptomatic bradycardia, various conduction disorders, orthostatic hypotension (feeling faint when you stand up), and syncope that can lead to falls, a particular danger in the elderly population that makes up a large share of glaucoma patients.¹¹ These effects are not everyday occurrences for most users, but they are well documented and clinically significant. The practical rule is simple: if you have asthma, severe COPD, second- or third-degree heart block, or an already-slow resting heart rate, timolol eye drops are generally contraindicated.

The CYP2D6 Problem and Drug Interactions

One of the less appreciated risks of timolol eye drops involves how the drug is broken down in the liver. Timolol is primarily metabolized by an enzyme called CYP2D6. Some people are born without a functional copy of this enzyme, and they clear timolol much more slowly, letting it accumulate to higher levels. But even people with normal CYP2D6 can run into trouble if they are also taking a drug that blocks the enzyme. The most common culprits are certain antidepressants: paroxetine and fluoxetine are potent CYP2D6 inhibitors.¹²

In a crossover study of healthy volunteers, taking paroxetine for just three days increased peak timolol levels by roughly 50 percent and total drug exposure by about 60 to 80 percent, depending on the formulation used. Six of twelve volunteers using the standard 0.5 percent timolol drops exceeded the plasma concentration threshold associated with systemic side effects.¹³ Laboratory experiments confirmed that paroxetine and fluoxetine are the strongest inhibitors of timolol breakdown, with sertraline somewhat weaker and citalopram weaker still.¹⁴

This matters because the overlap is common: glaucoma patients tend to be older adults, a population with high rates of depression. If your eye doctor prescribes timolol drops and your primary care physician prescribes paroxetine or fluoxetine, neither may realize the interaction exists unless someone flags it. If you are using timolol and start a new antidepressant, or vice versa, the combination is worth bringing up with both prescribers. The calcium channel blocker verapamil and the concurrent use of other oral beta-blockers also increase risk.

Neuropsychiatric Side Effects

Beyond the heart and lungs, timolol can affect the brain. Because it is lipophilic, it crosses the blood-brain barrier relatively easily. A review of adverse event reports found that among central nervous system cases linked to ophthalmic timolol, roughly 44 percent involved depression, psychosis, confusion, or hallucinations.¹⁵ These events represent a small proportion of all timolol users, but they are easy to misattribute. An older adult who develops new-onset depression or confusion after starting timolol eye drops may be incorrectly diagnosed with dementia, a mood disorder, or another neurological condition when the culprit is a drop they put in their eye twice a day.

The reassuring finding is that withdrawal of the drug usually resolves these effects within one to seven days.¹⁶ If you or a family member notices mood changes, vivid dreams, increased fatigue, or new confusion after starting timolol, it is worth mentioning to the prescribing doctor before assuming the cause is unrelated. Awareness of this connection, both among patients and the clinicians who treat them, remains lower than it should be.¹⁷

Reducing Systemic Side Effects With Proper Technique

A surprisingly simple maneuver can cut down on the amount of timolol that reaches your bloodstream: pressing a finger against the inner corner of your eye, or simply keeping your eyes closed, for one to two minutes after instilling the drop. This technique, called nasolacrimal occlusion or eyelid closure, blocks the drop from draining through the nasolacrimal duct and into the nasal mucosa. A review of the literature found that these methods improve the drug’s penetration into the eye itself while discouraging systemic absorption.¹⁸ It costs nothing, takes very little effort, and is one of the most undertaught skills in ophthalmology. If you are on timolol eye drops and nobody has told you about this, consider it free insurance.

Formulation Differences

Not all timolol eye drops are the same product in the same bottle. The standard formulation is a 0.25 or 0.5 percent aqueous solution applied twice daily. For patients who find twice-daily dosing burdensome, a gel-forming version exists. This product uses a polymer called gellan gum that turns into a gel when it contacts the ions in tear fluid, which keeps the drug on the eye surface longer. A six-month multicenter trial showed that this gel formulation given once daily was equally effective at lowering pressure as the standard solution given twice daily.¹⁹ Fewer drops per day also means less preservative exposure and less total drug reaching the bloodstream.

Preservative content is another practical consideration. Most standard timolol bottles contain benzalkonium chloride, a preservative that can irritate the eye surface over months and years of use, contributing to dry eye, redness, and stinging. Preservative-free unit-dose vials are available, and they cause less reduction in corneal sensitivity and are subjectively more comfortable.²⁰ For patients who need timolol long-term, asking about a preservative-free option can make a real difference in comfort and ocular surface health.

Timolol for Infantile Hemangiomas

One of the more unexpected chapters in timolol’s history is its use on infant skin. Infantile hemangiomas, the bright red raised birthmarks sometimes called strawberry marks, are caused by an overgrowth of blood vessels. The oral beta-blocker propranolol is now a standard treatment for large or problematic hemangiomas, and that success prompted interest in whether a topical beta-blocker like timolol could work for smaller, thinner ones.

A systematic review and meta-analysis pooled results from multiple studies and found that topical timolol produced a significantly higher rate of improvement compared with no treatment, with few adverse effects.²¹ However, a randomized trial comparing timolol gel with placebo found no significant difference in complete resolution at 24 weeks, though there was some improvement in color early in treatment, and no systemic side effects were observed.²² The evidence quality has been rated low to moderate overall. In practice, topical timolol is used for small, superficial hemangiomas where the stakes are cosmetic rather than functional, and oral propranolol remains the treatment when the hemangioma is large or threatens vision or airway.

Wound Healing

Dermatologists have been exploring topical timolol for a different purpose entirely: helping chronic wounds close. Beta-2 receptors on skin cells appear to play a role in slowing down the migration of keratinocytes, the cells that resurface a wound. By blocking those receptors, timolol may accelerate re-epithelialization. In a study of chronic leg ulcers, wounds treated with topical timolol in addition to standard care shrank by about 62 percent in area over 12 weeks, compared with roughly 30 percent in the control group.²³

A retrospective review of lower-leg surgical wounds in elderly patients found that adding topical timolol to standard wound care eliminated the healing disadvantage that patients with comorbidities, such as diabetes and peripheral vascular disease, normally experience. Those suboptimal healers using timolol healed in about the same time frame as healthier patients.²⁴ This is still considered off-label and the evidence base consists of smaller studies, but it is a growing area of clinical interest, particularly for patients with hard-to-heal wounds who have exhausted conventional options.

Timolol Eye Drops for Acute Migraine

Perhaps the most surprising off-label use of timolol eye drops is for treating migraine attacks. Oral beta-blockers have been used for migraine prevention for decades, but the idea of using timolol eye drops to abort an active migraine is relatively new. A randomized crossover trial found that about 82 percent of timolol-treated migraine attacks showed a meaningful reduction in pain within 20 minutes, compared with 14 percent of placebo-treated attacks. On average, pain scores dropped by about 4.6 points more in the timolol group.²⁵ An earlier crossover trial had also demonstrated effectiveness for acute migraine pain.²⁶

These results are striking, and the appeal is obvious: timolol eye drops are inexpensive, widely available, and act fast. But the evidence base is still thin compared to established migraine treatments. Both trials were crossover designs, meaning the same patients served as their own controls, which is efficient but not the same as a large parallel-group trial. The trials have not yet been replicated by independent groups. Timolol eye drops are not approved for migraine, and the same systemic absorption risks apply. For someone who gets migraines and also has asthma, this would be a poor choice. Still, for the right patient, the data are interesting enough that some headache specialists have begun experimenting with it.²⁷

Veterinary Use

Timolol eye drops are not limited to human medicine. Dogs and cats develop glaucoma, and timolol is part of the veterinary toolkit as well. In a study of glaucomatous dogs, timolol alone lowered pressure by about 3.8 mmHg after four days, though a carbonic anhydrase inhibitor (dorzolamide) and the combination of dorzolamide plus timolol both achieved larger reductions of roughly 7.5 and 8.4 mmHg, respectively.²⁸ As in humans, combination therapy tends to work better than timolol alone. Veterinary ophthalmologists also face the same systemic absorption concerns, particularly in small-breed dogs where the relative dose-to-body-weight ratio is higher, and monitor for bradycardia just as human clinicians do.